On behalf of CHC's subsidiary,Chiu Ho Biotech
Co., Ltd. to announce capital reduction resolved by
Board of Directors.
Date of events
2022/06/27
To which item it meets
paragraph 11
Statement
1.Date of the board of directors resolution:2022/06/27
2.Reason for capital reduction:Cash refund
3.Amount of capital reduction:NT$ 50,000,000
4.Cancelled shares:5,000,000 shares
5.Capital reduction percentage:19.23%
6.Share capital after capital reduction:NT$ 210,000,000
7.Scheduled date of the shareholders meeting:NA
8.Estimated no.of listed common shares after issuance of new shares
upon capital reduction:NA
9.Estimated ratio of listed common shares after issuance of new shares upon
capital reduction to outstanding common shares:NA
10.Please explain any countermeasures for lower circulation in
shareholding if the aforesaid estimated no.of listed common shares upon
capital reduction does not reach 60 million and the percentage does not
reach 25%:NA
11.The record date for capital reduction:2022/07/01
12.Any other matters that need to be specified:Resolved by Board of Directors
as authorized by shareholders' meeting.
Attachments
Original Link
Original Document
Permalink
Disclaimer
CHC Healthcare Group published this content on 27 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 June 2022 11:24:02 UTC.
CHC Healthcare Group is a Taiwan-based investment holding company. The Company primarily involves in the agent distribution of radiation oncology, neurology, medical image and nuclear medical, as well as dental and ophthalmological equipment and instrument. The Company also offers related maintenance and leasing services, components and consumable materials and specialty consulting services. The Company deals with medical instrument with brands as Elekta, PTW, GE, Ashland, Megin, Leica, Hillrom, Sony, Ellex and Wexler, among others. The Company is also involved in the operation of pharmacy.
CHC HEALTHCARE GROUP 
